Role of FDG-PET/CT in prediction of pathological tumor response and survival after trimodality therapy for esophageal squamous cell carcinoma
© Hamai et al. 2015
Published: 16 December 2015
Trimodality therapy has frequently been applied to patients with locally advanced esophageal cancer. However, to preoperatively predict the response to neoadjuvant therapy and prognosis is difficult.
The present study aimed to determine the diagnostic applicability of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) to evaluating the response and prognosis after trimodality therapy for esophageal squamous cell carcinoma (ESCC).
The responses of 111 patients with ESCC who underwent neoadjuvant chemoradiotherapy (nCRT) followed by surgery were monitored by measuring the maximal standardized uptake value (SUVmax) of the primary tumor on FDG-PET before and after nCRT. Associations between SUVmax and pathological response of primary tumor and prognosis were analyzed.
We compared the SUVmax between good (Japan Esophageal Society response evaluation criteria grades 3/2; n = 87, 78.4 %) and poor (grade 1; n = 24, 21.6 %) responders. The SUVmax after nCRT (post-SUVmax) in good and poor responders were 2.7 ± 0.9 and 4.4 ± 2.2, respectively (p < 0.0001). The rates of the SUVmax decrease after nCRT (ΔSUVmax) in these patients significantly differed (71 ± 14% vs. 60 ± 21%, respectively, p = 0.003). The area under receiver operating characteristic curves (AUC) showed that the optimal cut-off for post-SUVmax and ΔSUVmax were 3.7 (AUC, 0.76; 95% CI, 0.63-0.89; P < 0.001) and 70% (AUC, 0.65; 95% CI, 0.52-0.78; P = 0.02) for predicting good responder, respectively, and that the patients could be separated into groups with and without good response using these cut-off values. The 5-year overall survival rate was significantly higher for patients with ΔSUVmax > 70% than ≥ 70 % (66% vs. 42%, p = 0.04), and multivariable analysis including preoperative factors also revealed ΔSUVmax (≥ 70/> 70%) as an independent prognostic factor for disease-specific survival (OR, 2.22; 95%CI, 1.02 - 4.76; p = 0.04).
Post-SUVmax and ΔSUVmax were valuable preoperative factors for predicting tumor response and survival in patients with ESCC after trimodality therapy. Thus, FDG-PET/CT findings are useful for tailoring optimal therapies for individual patients with ESCC.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.